TrialJournal of diabetes investigation2024

A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02).

Yushi Hirota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.